Research & Development

EpicentRx closes $35m series D financing to support development of small molecule immunotherapy and oncolytic viral platform

EpicentRx, a clinical cancer immunotherapy company targeting both sides of the immune system to deliver cancer treatments with minimal toxicity, announced today that it has raised a $35 million Series D financing using the Silicon Valley based life-science focused investment bank, Biotech Alliances International.

Finch Therapeutics, Takeda expand collaboration to develop microbiome therapeutics

Finch Therapeutics Group, Inc. (“Finch”) and Takeda Pharmaceutical Company Limited (“Takeda”; TSE:4502/NYSE:TAK) announced today the expansion of their collaboration to develop microbiome-based therapeutics using Finch’s Human-First Discovery platform.

RDD Pharma signs LOI to acquire Naia Rare Diseases

RDD Pharma, a company focused on orphan and innovative therapies for gastrointestinal disorders entered into a non-binding letter of intent (LOI) to acquire Naia Rare Diseases ("Naia"), a biopharmaceutical company developing drugs for Short Bowel Syndrome ("SBS") and other rare gastrointestinal diseases.

Merck to acquire Calporta Therapeutics for $576m

COI Pharmaceuticals announced that Merck has agreed to acquire Calporta Therapeutics in a deal valued at around $576m.

NEC and VAXIMM announce collaboration to advance personalized neoantigen cancer vaccines

NEC has the option for development and commercialization rights to the program worldwide, except for China and other Asian territories outside of Japan

ATAI Life Sciences and Cyclica launch joint venture to revolutionise drug development for mental health disorders

ATAI Life Sciences AG, a global biotech platform that envisions an end to mental illnesses, and Cyclica Inc., a leading biotechnology company that leverages artificial intelligence and computational biophysics to streamline the drug discovery process, have launched a joint venture aimed at changing the paradigm in which mental health disorders are treated.

Stone Capital Partners Biosyngen to setup $50m biopharmaceutical investment fund in Singapore

Stone Capital and Biosyngen have partnered to establish a Biopharmaceutical Investment Fund in Singapore, the signing ceremony was held in Ascendas One Hub of Sino-Singapore Guangzhou Knowledge City.

Regeneron, Vyriad sign deal to develop oncolytic virus-based treatments

Regeneron Pharmaceuticals has entered into a research collaboration and option licencing agreement with Vyriad to discover and develop new oncolytic (cancer-killing) virus-based treatments for various forms of cancer.

Cyclica collaborates with Enamine to use REAL technology in its ligand design platform for AI-augmented drug design

Cyclica, Inc. today announced a collaboration with Enamine Ltd., the world’s largest chemical supplier, to explore its huge readily accessible chemical space using Cyclica’s state-of-the-art AI-driven Ligand Design platform.